<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868526</url>
  </required_header>
  <id_info>
    <org_study_id>2021P000683</org_study_id>
    <nct_id>NCT04868526</nct_id>
  </id_info>
  <brief_title>Dietary Intervention to Mitigate Adverse Consequences of Night Work</brief_title>
  <official_title>Food Timing to Mitigate Adverse Consequences of Night Work</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shift work increases the risk for diabetes possibly due to the adverse metabolic effects of&#xD;
      circadian misalignment. As shift work is not foreseen to disappear, the development of&#xD;
      individually-targeted therapies for metabolic health in these vulnerable shift workers is&#xD;
      urgently needed. This research will determine whether our dietary intervention can mitigate&#xD;
      the adverse metabolic effects of circadian misalignment, which may help in the design of&#xD;
      evidence-based dietary interventions to improve the metabolic health in shift workers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline glucose tolerance on test day</measure>
    <time_frame>Baseline and Days 5-6</time_frame>
    <description>Change in incremental glucose area under the curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in microbial community structure assessed by shotgun sequence data from oral and gut microbiome</measure>
    <time_frame>Baseline and Days 5-6</time_frame>
    <description>Shotgun metagenomics sequencing in saliva, stool, and rectal swab samples for in-depth interrogation of the microbial community structure (species taxonomic level) and function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Insulin sensitivity Index by the Oral Minimal Model on test day</measure>
    <time_frame>Baseline and Days 5-6</time_frame>
    <description>Derived by the Oral Minimal Model based on glucose and insulin profile after a mixed meal test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline levels of serum markers of gut microbiota, intestinal barrier integrity and inflammatory state on test day</measure>
    <time_frame>Baseline and Days 5-6</time_frame>
    <description>Serum markers of gut microbiota (SCFA), intestinal barrier integrity (zonulin, LPS and LBP, and inflammatory state (cytokines)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Dietary Habits</condition>
  <arm_group>
    <arm_group_label>Control-Dietary Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control condition first, then to Dietary intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietary intervention-Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary intervention first, then to Control condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>dietary intervention</intervention_name>
    <description>manipulate feeding-fasting cycle to be aligned or misaligned with the circadian system</description>
    <arm_group_label>Control-Dietary Intervention</arm_group_label>
    <arm_group_label>Dietary intervention-Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants will be younger (18-45 y), healthy, non-diabetic with BMI 20-30,&#xD;
             European/Hispanic/African-American ancestry, and without medication use (excepting&#xD;
             oral contraceptives). Participants must be free from acute, chronic, or debilitating&#xD;
             medical conditions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  We will exclude people with reported or actigraphically measured habitual outpatient&#xD;
             sleep durations of &lt;5h or &gt;9h and people who have recently (within last 6 months)&#xD;
             taken antibiotics.&#xD;
&#xD;
          -  major visual or auditory handicaps&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frank AJL Scheer</last_name>
    <phone>6177327014</phone>
    <email>FSCHEER@BWH.HARVARD.EDU</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jingyi Qian</last_name>
    <phone>6175257423</phone>
    <email>jqian@bwh.harvard.edu</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Frank AJL Scheer, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

